Eli Lilly and Company (NYSE:LLY) Issues FY 2026 Earnings Guidance

Eli Lilly and Company (NYSE:LLY) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided EPS guidance of 33.500-35.000 for the period, compared to the consensus EPS estimate of 33.280. The company issued revenue guidance of $80.0 billion-$83.0 billion, compared to the consensus revenue estimate of $77.5 billion.

Eli Lilly and Company Trading Down 7.3%

Eli Lilly and Company stock traded down $81.00 during mid-day trading on Thursday, hitting $1,026.13. 4,454,307 shares of the stock were exchanged, compared to its average volume of 3,282,194. The stock has a market capitalization of $970.08 billion, a price-to-earnings ratio of 50.34, a PEG ratio of 0.76 and a beta of 0.39. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The firm’s fifty day simple moving average is $1,054.31 and its two-hundred day simple moving average is $895.30.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The firm had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same quarter last year, the firm posted $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be given a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is presently 29.35%.

Analyst Ratings Changes

A number of equities analysts have weighed in on LLY shares. TD Cowen upped their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Thursday, January 29th. Daiwa Capital Markets set a $1,230.00 price target on shares of Eli Lilly and Company and gave the company a “buy” rating in a report on Tuesday, December 16th. BMO Capital Markets reiterated an “outperform” rating and issued a $1,300.00 price target on shares of Eli Lilly and Company in a report on Thursday. HSBC reaffirmed a “hold” rating and issued a $1,070.00 target price on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Finally, Berenberg Bank increased their price target on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the company a “hold” rating in a report on Tuesday, December 2nd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,201.17.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 beat and strong 2026 guidance — Lilly reported revenue of ~$19.3B and EPS above estimates, and guided 2026 revenue and EPS above consensus, underpinning the recent rally. Earnings/Guidance
• Positive Sentiment: Analysts raising targets — Multiple firms lifted price targets (e.g., Morgan Stanley to $1,313; Cantor Fitzgerald to $1,205) and kept overweight/buy ratings, signaling continued analyst confidence despite recent volatility. Analyst Targets
• Positive Sentiment: Capacity investments support volume strategy — Lilly is expanding manufacturing (including a ~$3.5B Pennsylvania facility) to convert price pressure into volume growth, reducing future supply constraints. Factory Investment
• Neutral Sentiment: Broader GLP‑1 market growth — Positive trial news from big pharma (e.g., Pfizer Phase 2b) expands the overall market but also brings more competitors; that’s a long-term tailwind for demand but mixed for incumbents’ share. Pfizer GLP-1
• Neutral Sentiment: Smaller biotech entrants — Early-stage competitors (e.g., Structure Therapeutics moving a GLP‑1 pill into Phase 3) add long-term R&D noise but are unlikely to dent Lilly’s near-term cash flows. Structure Therapeutics
• Negative Sentiment: Competitive pricing shock from Hims & Hers — News that a telehealth retailer will sell a $49 copy of a GLP‑1 pill (marketing a low‑cost alternative) triggered immediate investor concern about pricing erosion and prompted sectorwide selling. That headline is the primary near-term reason the stock is down. Hims & Hers $49 pill
• Negative Sentiment: Profit-taking and volatility after a big run — After a large intraday surge on earnings, some investors trimmed positions; when combined with the Hims & Hers headline, that accelerated the pullback. Why LLY Dropped

Institutional Trading of Eli Lilly and Company

Large investors have recently made changes to their positions in the company. Turning Point Benefit Group Inc. acquired a new stake in shares of Eli Lilly and Company during the 3rd quarter worth about $56,000. Graney & King LLC increased its stake in Eli Lilly and Company by 14.6% in the second quarter. Graney & King LLC now owns 181 shares of the company’s stock valued at $141,000 after purchasing an additional 23 shares during the last quarter. Imprint Wealth LLC acquired a new stake in shares of Eli Lilly and Company during the third quarter worth about $142,000. Mpwm Advisory Solutions LLC grew its position in shares of Eli Lilly and Company by 11.9% during the third quarter. Mpwm Advisory Solutions LLC now owns 253 shares of the company’s stock worth $193,000 after acquiring an additional 27 shares during the last quarter. Finally, Chapman Financial Group LLC purchased a new stake in shares of Eli Lilly and Company in the second quarter valued at approximately $198,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.